-+ 0.00%
-+ 0.00%
-+ 0.00%

Larimar Therapeutics Q3 EPS $(0.61) Misses $(0.40) Estimate

Benzinga·11/05/2025 12:09:34
Listen to the news
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.40) by 51.36 percent. This is a 154.17 percent decrease over losses of $(0.24) per share from the same period last year.